Because of the large size of the FANCD2 and BRIP1/BACH1 genes, however, we screened a smaller number of non-BRCA1/2 breast cancer families for mutations in these genes (30 and 75 families, respectively), but they were selected on the basis of all the available affected individuals sharing a haplotype around FANCD2 or BRIP1/BACH1, having at least one case of ovarian cancer (FANCD2), or having had full sequence analysis of BRCA1 and BRCA2 (BRIP1/BACH1). This evidence concerns the gene FANCD2 and ovarian cancer.